The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort.
 
Sophie Cousin
No Relationships to Disclose
 
Carine A. Bellera
Consulting or Advisory Role - Bristol-Myers Squibb
 
Jean Philippe Guégan
No Relationships to Disclose
 
Fabienne Portales
Honoraria - Sanofi; SERVIER (Inst)
Travel, Accommodations, Expenses - ipsen; Novartis
 
Antoine Hollebecque
Honoraria - Amgen; Eisai; Incyte; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Spectrum Pharmaceuticals (Inst)
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Jean Philippe Metges
No Relationships to Disclose
 
Philippe Alexandre Cassier
Honoraria - Amgen; ITeos Therapeutics; Janssen
Consulting or Advisory Role - OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Roche
 
Carlos A. Gomez-Roca
Honoraria - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech
Travel, Accommodations, Expenses - MSD Oncology; Pierre Fabre; Roche/Genentech
 
Fanny Bouteiller
No Relationships to Disclose
 
Michèle Kind
Consulting or Advisory Role - Keosys
 
Jean Palussière
Honoraria - Boston Scientific
Speakers' Bureau - Philips Healthcare
Research Funding - Boston Scientific
 
Simon Pernot
Honoraria - Amgen; AstraZeneca; Bayer; Merck Serono; Pierre Fabre; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Merck Serono; Pierre Fabre
Travel, Accommodations, Expenses - Amgen; Roche; Servier/Pfizer
 
Isabelle Soubeyran
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; Takeda
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst)
 
Alban Bessede
Employment - Explicyte Immuno-Oncology
Leadership - Explicyte Immuno-Oncology
Stock and Other Ownership Interests - Explicyte Immuno-Oncology
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS